PROTAC as a novel drug discovery modality is gaining more and more attention, largely because of Arvinas’ success with its AR and ER PROTACs, now both in phase II clinical trials. It is not exaggerating to say that almost all big pharma are engaged in protein degradation, one way or the other, in addition to dozens of biotech companies explicitly founded on the platform of protein degradation. Kumera, C4, and Nurix are just a few prominent examples. For Amgen, nearly a third of its discovery programs are somewhat related to protein degradation. As far as the latest developments are concerned, novel E3 ligase ligands have been intensively pursued. With dozens of PROTACs in clinical trials, there is no doubt that a PROTAC drug will gain the FDA approval, sooner or later, most likely sooner.